Car-T Central
  • CAR-T Fundamentals
  • CAR-T in Australia
  • Clinical Management
  • Expert Opinion
  • About Us
  • Register
Car-T Central
  • CAR-T Fundamentals
  • CAR-T in Australia
  • Clinical Management
  • Expert Opinion
  • About Us
  • Register

Yescarta

Axicabtagene Ciloleucel (Yescarta®) is now publicly funded in Australia for relapsed or refractory DLBCL, PMBCL, TFL and HGBCL

Kite, A Gilead company, have announced that its CAR-T cell therapy, axicabtagene ciloleucel (Yescarta®), is now publicly funded and available for the treatment of patients with relapsed or refractory CD-19 […]

Privacy Policy © Copyright Bastion Brands 2022